Clinical Trials

1,314 enrolled

Prostatic Neoplasms

NCT02960022 2026-04-13

A Study for Subjects With Prostate Cancer Who Previously Participated in an Enzalutamide Clinical Study

900 enrolled

Prostatic Neoplasms

NCT05818683 2026-04-13

A Study of Pasritamig (JNJ-78278343) in Combination With Other Agents for Metastatic Prostate Cancer

300 enrolled

Metastatic Castration-resistant Prostate Neoplasms

NCT05901649 2026-04-13

ArtemisPRO

Active not recruiting

504 enrolled

Metastatic Hormone-sensitive Prostate Cancer

NCT06863272 2026-04-13

IDeate-Prostate02

Phase 1/2 Recruiting

360 enrolled

Neoplasm Metastasis, Prostatic Neoplasms, Castration-Resistant

NCT07406282 2026-04-09

Double-DARE

Recruiting

1,400 enrolled

Prostatic Neoplasms

NCT06136624 2026-04-08

OMAHA-003

1,310 enrolled

Prostate Cancer Metastatic

NCT07287150 2026-04-08

InavoPC

100 enrolled

Phase 3 Active not recruiting

Metastatic Castration-Resistant Prostate Cancer

NCT04821622 2026-04-07

Study of Talazoparib With Enzalutamide in Men With DDR Gene Mutated mCSPC

599 enrolled

Prostatic Neoplasms

NCT06120491 2026-04-03

EvoPAR-PR01

1,800 enrolled

Prostatic Neoplasms

NCT04221542 2026-03-30

Study of AMG 509 in Participants With Metastatic Castration-Resistant Prostate Cancer

479 enrolled

Bites and Stings, Prostatic Neoplasms

NCT07028853 2026-03-30

MEVPRO-3

1,000 enrolled

Prostatic Neoplasms

NCT05526248 2026-03-11

ARAMON

Phase 2 Completed

28 enrolled 14 charts

Biochemically Recurrent Prostate Cancer

NCT04179864 2026-03-10

CELLO-1

Phase 1/2 Terminated

102 enrolled 39 charts

Prostatic Neoplasms

NCT06691984 2026-03-06

Phase 3 Study of Xaluritamig vs Cabazitaxel or Second Androgen Receptor-Directed Therapy in Participants With Progressive Metastatic Castration-Resistant Prostate Cancer (XALute)

675 enrolled

Neoplasms, Prostatic Neoplasms

NCT06551324 2026-03-04

MEVPRO-1

600 enrolled

Prostatic Neoplasms, Recurrence

NCT07230106 2026-03-03

A Study of SHR3680, HS-20093 and SHR2554 in Subjects With Prostate Cancer

218 enrolled

Prostatic Neoplasms

NCT06257693 2026-02-27

Enzalutamide Implants (Enolen) in Patients With Prostate Cancer

56 enrolled

Prostate Adenocarcinoma

NCT05968599 2026-02-25

A Study to Learn About the Study Medicines Called Enzalutamide and Abiraterone in People With Metastatic Castration-resistant Prostate Cancer

2,731 enrolled 14 charts

Prostatic Neoplasms, Castration-Resistant

NCT05997615 2026-02-24

AMX-500

390 enrolled

Prostatic Neoplasms, Prostatic Neoplasms, Castration-Resistant

NCT06855277 2026-02-24

AcTFirst

940 enrolled

Prostatic Neoplasms

NCT02861573 2026-02-17

KEYNOTE-365

Phase 1/2 Recruiting

1,200 enrolled

DermatologicGastrointestinalGenitourinaryHead & NeckThoracic

Metastatic Castration-Resistant Prostate Cancer

NCT05551117 2026-02-09

Tamarack

Phase 2 Terminated

192 enrolled 20 charts

Squamous Cell Carcinoma of Head and Neck, Anus Neoplasms, Carcinoma, Non-Small-Cell Lung, Melanoma, Carcinoma, Small Cell, Small Cell Lung Carcinoma, Prostatic Neoplasms, Castration-Resistant

NCT04729114 2026-02-04

A Safety and Dose-finding Study of PRL-02 Depot in Men With Advanced Prostate Cancer

174 enrolled

Neoplasm Metastasis, Prostatic Neoplasms

NCT05701007 2026-01-29

Real World Evidence Study on Metastatic Prostate Cancer in the Pirkanmaa Hospital District in Finland

1,083 enrolled 29 charts

Neoplasm Metastasis, Prostatic Neoplasms

NCT06764485 2026-01-28

rechARge

960 enrolled

1,401 enrolled 25 charts 1 FDA

Prostatic Neoplasms, Bulbo-Spinal Atrophy, X-Linked

NCT02003924 2026-01-27

PROSPER

Phase 3 Completed

Prostatic Neoplasms

NCT03338790 2026-01-27

CheckMate 9KD

Phase 2 Completed

292 enrolled 21 charts

Phase 3 Active not recruiting

Prostatic Neoplasms

NCT04647526 2026-01-13

SPLASH

455 enrolled 18 charts

Prostatic Neoplasms

NCT06072196 2025-12-31

A Study to Learn About Novel Hormonal Therapies in People With Metastatic Castration-Sensitive Prostate Cancer (mCSPC)

3,017 enrolled 5 charts

Prostatic Neoplasms

NCT06228053 2025-12-22

SYNERGY-201

53 enrolled

Metastatic Castration-resistant Prostate Cancer

NCT05457257 2025-12-19

Clinical Study to Assess the Efficacy and Safety of Olaparib in Chinese Patients With Metastatic Castration-Resistant Prostate Cancer Who Have Failed Prior Treatment With a New Hormonal Agent and Have BRCA1/2 Mutations

Phase 4 Completed

43 enrolled 16 charts

Phase 3 Active not recruiting

Metastatic Castration-resistant Prostate Cancer

NCT04446117 2025-12-18

CONTACT-02

575 enrolled 13 charts

Prostatic Neoplasms

NCT04034095 2025-12-15

A Registry Study to Observe Clinical Outcomes of Participants With High-risk Metastatic Hormone-naïve Prostate Cancer in Japan

979 enrolled

Phase 1/2 Active not recruiting

Prostatic Neoplasms

NCT05367440 2025-12-08

PETRANHA

174 enrolled

Prostatic Neoplasms

NCT07086651 2025-12-08

A Study to Learn About Two Medicines (Apalutamide and Enzalutamide) in People With Metastatic Castration-sensitive Prostate Cancer (mCSPC)

1,300 enrolled

DermatologicGastrointestinalGenitourinaryGynecologicHead & NeckThoracic

Prostatic Neoplasms

NCT05914116 2025-11-21

A Phase 1/2a Study of DB-1311/BNT324 in Advanced/Metastatic Solid Tumors

Phase 1/2 Recruiting

862 enrolled

Squamous Cell Carcinoma of Head and Neck, Esophageal Squamous Cell Carcinoma, Carcinoma, Non-Small-Cell Lung, Uterine Cervical Neoplasms, Carcinoma, Hepatocellular, Melanoma, Prostatic Neoplasms, Small Cell Lung Carcinoma

NCT05252390 2025-11-06

NUV-868 as Monotherapy and in Combination With Olaparib or Enzalutamide in Adult Patients With Advanced Solid Tumors

Phase 1 Terminated

82 enrolled

BreastGastrointestinalGenitourinaryGynecologic

Breast Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Prostatic Neoplasms, Castration-Resistant, Triple Negative Breast Neoplasms

NCT02294461 2025-10-24

An Asian Study to Evaluate Efficacy and Safety of Oral Enzalutamide in Progressive Metastatic Prostate Cancer Participants

Phase 3 Completed

395 enrolled 25 charts

1,150 enrolled 23 charts 2 FDA

Prostatic Neoplasms, Bulbo-Spinal Atrophy, X-Linked

NCT02677896 2025-10-24

ARCHES

Phase 3 Completed

Metastatic Hormone Sensitive Prostate Cancer

NCT03939689 2025-10-14

ARROW

Phase 2 Completed

120 enrolled 21 charts

Phase 2 Active not recruiting

Prostatic Neoplasms

NCT04557449 2025-10-01

CDK4i

362 enrolled

BreastGastrointestinalGenitourinarySarcomaThoracic

Adenocarcinoma of Lung, Breast Neoplasms, Liposarcoma, Prostatic Neoplasms, Colorectal Neoplasms

NCT07198633 2025-09-30

A Clinical Study of QLC5508 and/or QLH12016 in Combination With Other Anti-tumor Therapies in Subjects With Advanced Prostate Cancer

Phase 1/2 Not yet recruiting

212 enrolled

Advanced Prostate Cancer

NCT05588609 2025-09-18

Study Evaluating Zenocutuzumab in Patients With or Without Molecularly Defined Cancers

Phase 2 Terminated

13 enrolled

GenitourinaryThoracic

NSCLC Harboring NRG1 Fusion

NCT05202301 2025-08-11

A Study Using Available Data to Learn to What Extent Patients With Prostate Cancer Who Received Second Generation Androgen Receptor Inhibitors Took Their Medication as Prescribed or Stopped Taking Their Medication Completely

13,779 enrolled

Prostatic Neoplasms

NCT05413421 2025-08-11

Study of ORIC-944 in Patients With Metastatic Prostate Cancer

250 enrolled